Herpesvirus saimiri (HVS) has the capacity to incorporate large amounts of heterologous DNA and can infect many different human cell types. To develop its potential as a gene therapy vector, we cloned herpes simplex virus thymidine kinase (TK) gene into the HVS genome in the form of an enhanced green fluorescent protein (EGFP) fusion protein, using a cosmid-based approach. At multiplicity of infection ¼ 100 over 90% of human leukemic K562 and Jurkat cells were transduced with HVS/EGFP-TK. Conditions of no selective pressure expression were maintained at 492% per cell division. Expression of the EGFP-TK fusion protein rendered transfected leukaemic cells sensitive to cytotoxic treatment with the prodrugs ganciclovir (GCV) and (E)-5-(2-bromovinyl)-2 0 deoxyuridine (BVDU) at concentrations as low as 10 ng/ml. The viral vector was also screened against a panel of colorectal and pancreatic carcinoma cell lines. All cell lines were transduced but showed a range of sensitivity to infection. Three of the most easily transduced cell lines: Mia PaCa, HCT116 and SW948 transduced with HVS/EGFP-TK were effectively ablated by subsequent treatment with GCV or BVDU. Our results show that in its current form HVS/EGFP-TK could be utilized as an antitumour agent, or it could be developed further by inclusion of a therapeutic gene, with TK presence ensuring a mechanism of controlled removal of modified cells when no longer necessary. These results suggest that HVS/EGFP-TK has a great potential for a number of gene therapy applications.
I n order to improve the biological safety of gene therapy vectors, a metabolic suicide gene is often incorporated. The current most commonly used suicide gene system is the thymidine kinase (TK) gene from herpes simplex virus (HSV), 1 which can activate a number of safe prodrugs 2 (nucleoside analogues) into toxic metabolites, allowing selective elimination of transduced cells. Ganciclovir (GCV) and (E)-5-(2-bromovinyl)-2'deoxyuridine (BVDU) are two such prodrugs that are metabolized into monophosphate forms by the action of TK and may be further phosphorylated by cellular enzymes. GCV triphosphate inhibits DNA polymerase by terminating DNA synthesis during replication and can induce apoptosis in cells infected by HSV. 1, 3, 4 BVDU kills HSV-infected cells by BVDU triphosphate inhibiting viral DNA polymerase. 5 The mode of BVDU action in TK-transduced cells is possibly different and may involve BVDU-monophosphate inhibition of cellular thymidylate synthase (TS), 6 however, this theory is under review. 7 Although phosphorylated GCV and BVDU are not membrane permeable, these metabolites can pass through gap junctions into neighbouring noninfected cells and cause cell death by the ''bystander effect''. 1 In in vitro settings BVDU is a more efficient and less toxic prodrug than GCV, 7, 8 but has a much less potent bystander effect than GCV in HSV-TK-transduced human glioma cells. 9, 10 Gene delivery systems that are currently being evaluated by clinical trials include retroviruses, lentiviruses, foamiviruses, adeno and adenoassociated viruses, herpesviruses and cationic liposomes/DNA-protein complexes. So far, TK gene has been delivered by retroviruses and adenoviruses in in vitro [11] [12] [13] [14] and in vivo [15] [16] [17] applications. Retroviruses are the most widely studied, have a broad cell tropism and no toxic effect on infected cells, but can only infect dividing cells. 18 Stable gene transfer is facilitated by viral genome integration into the host chromosome, 19 but this carries an associated risk of insertional mutagenesis/oncogene activation. 20 Indeed current trials with X-linked SCID patients were stopped because of this, when patients developed leukaemia. 21 Although retroviruses can be produced at relatively high titres (10 6 -10 7 cfu/ml), they have a low transfection efficiency in vivo and may form replication-competent virus by homologous recombination. 22 Adenoviruses infect nondividing and dividing cells, have a high gene transfer rate 23 and cause transiently high levels of gene expression. 24 They can be produced at high titres but host immune response may neutralize vector particles before gene transfer and can cause inflammatory and toxic reactions in patients. 24 As the adenoviral genome is not incorporated into the host genome, there is less risk of insertional mutagenesis but no long-term gene expression.
TK has also been expressed in human T cells, using a herpesvirus saimiri (HVS) vector by Hiller et al (2000) . 25 This virus is a gamma-2 herpesvirus endemic in squirrel monkeys (Saimiri sciureus), 26 which can be produced at high titres (10 8 CFU/ml) in vitro. HVS does not integrate into the cellular genome but persists as a stable episome, 27 which can give rise to long-term expression in T cells without yielding infectious progeny. 25 The HVS genome possesses a large proportion of highly repeated DNA (H-DNA), which can be partially replaced with foreign DNA. 28 HVS has also been shown to infect and persist in a wide range of human cell lines, including primary human bone marrow stromal cells 29 and human carcinoma cell lines. 28, 30, 31 Unlike the related herpes simplex virus (HSV), HVS has low cytotoxicity in human cells, although it can, by means of viral oncogenes Stp and Tip cause human T cells to continuously proliferate. 32, 33 The primary objective of this study was to develop a HVS-based gene therapy vector, which after a time interval could be ablated by means of drug administration. Such a vector could then be further modified to include an expression cassette for a gene of therapeutic interest. Another application of a successful suicide vector would be to transduce and kill carcinoma cells. In order to facilitate identification of the transfected cell and to indicate gene expression the TK gene was cloned as a C-terminal fusion product to enhanced green fluorescent protein (EGFP) gene 34 into an attenuated nononcogenic Stp and Tip deleted HVS C488 strain. The HVS/EGFP-TK vector could infect and be maintained without selection in leukaemic (Jurkat and K562), pancreatic and colorectal carcinomal cell lines. HVS/ EGFP-TK-transduced cells were efficiently eliminated after the administration of GCV or BVDU, indicating functional expression of the EGFP-TK construct. This completed the first step of developing HVS as a gene therapy vector.
Results

Construction of a recombinant HVS vector containing EGFP-TK fusion gene (HVS/EGFP-TK)
The entire coding sequence for TK gene was PCR amplified from HSV virus (type 17) and fused, in frame, to the 3 0 -end of the EGFP gene present in cosmid 331EGFPDBst1107I (as described in Materials and methods and is shown in Fig 1) . DNA sequencing of the cosmid 331EGFP-TKDBst1107I confirmed cloning of HSV type 1 TK gene (Genbank X14112 bp in frame into the BamH1 site of the EGFP gene (C1-EGFP Genbank U55763 bp 606-1410). There were two silent mutations in the TK sequence and one aminoacid change from alanine to threonine at codon 334 in TK enzyme. All three base changes were probably due to differences in the sequence of TK between HSV type 17 and type 1. Although amino-acid mutations in TK can either enhance or destroy TK activity, 35, 18 the observed change did not occur in the known significant region between codons 159 and 174 of the putative nucleoside binding site. 35 Cotransfection of linearized cosmids into OMK cells required all the five cosmids to be present in a single cell before the generation of the virus HVS/EGFP-TK and subsequent plaque development could occur (Fig 2) . Fusion with the EGFP gene allowed the progression of viral infection of cells to be monitored easily and could indicate TK gene expression. Small plaques arising from single-cell recombination events, increased in size as adjacent cells were infected. In the centre of plaques cells were rounded off and detached/ lysed spreading the infection to nonadjacent OMK cells. When 50% of the cells had been detached, the cells and the supernatant were harvested and used as an inoculum for propagation of the virus. Semipurified viral stocks were titred at 1.5 Â 10 8 plaque-forming units (PFU)/ml. Expression of the EGFP-TK fusion protein was investigated by immunoblotting whole-cell lysates from OMK cells infected with HVS/EGFP-TK or HVS/EGFP (analogous control virus containing EGFP gene only) using an anti-GFP antibody (Fig 3) . Expression of the EGFP-TK fusion protein was demonstrated by a change in molecular weight from B30 kDa for EGFP to the expected B70 kDa for EGFP-TK. Expected protein sizes were estimated from the known gene size using the factor: 1 kb DNAE333 amino acids E37 kDa. 
Analysis of susceptibility of human cells to infection by HVS/EGFP-TK
The HVS/EGFP-TK vector could transduce human cells with high efficiency. As it had been demonstrated previously that Jurkat cells could be transduced with HVS to a significant level, 31 we infected Jurkat cells with HVS/EGFP-TK over a range of MOI (Fig 4a) . Highly susceptible K562 cells (our unpublished data) and permissive OMK cells were also included in the analysis. by HVS/EGFP-TK and a lineage correlation between the amount of virus applied and the levels of infection, as was observed for the range of MOIs tested (Fig 4a) . These experiments also showed that relatively low MOIs (below and up to 100) could be used in experiments to monitor functional activity of TK upon HVS/EGFP-TK infection of these cells with viability greater than 95% observed in all experiments.
The HVS viral genome is maintained as a selfreplicating episome in infected nonpermissive human cells, at least under conditions of selective pressure. 27 Therefore, we investigated the stability of transduction of continuously growing cultures of K562 and Jurkat cells infected with HVS/EGFP-TK or control HVS/ EGFP vectors, over a period of 80 days (Fig 4b and c) . The rationale behind these experiments was three-fold: first, to assess whether episomal gene expression can be maintained in these cells in the absence of selective pressure; second, to compare the levels of expression of TK-containing episome with that of the control episome; and finally, to establish whether already infected K562 and Jurkat cells could be expanded without significant loss of TK gene expression for use in future functional assays of TK activity. Based on an estimate of one cell division in 24 hour for both cell lines GFP þ expression was maintained in transduced K562 cells at 9277% per division (HVS/EGFP-TK) or 9674% per division (HVS/EGFP), and in Jurkat cells as 9373% per division (HVS/EGFP-TK) or 9472%per division (HVS/EGFP). Therefore, we concluded that the initial levels of transduction (determined by MOI) and not the type of vector are decisive for the longevity of episomal gene expression. This meant that for functional assays of TK activity in the infected cells, we could use less amount of virus and simply expand already infected cells for several rounds in order to obtain the cell numbers required.
Analysis of functional expression of TK, rendering HVS/ EGFP-TK-infected K562 cells sensitive to GCV and BVDU (TK assay)
The next step was to assess the level of functional expression of the EGFP-TK fusion protein in these cells. For this, we infected K562 and Jurkat cells with HVS/ EGFP-TK (at an MOI ¼ 100), expanded them for 4-7 days and analyzed the proportion of GFP þ cells following treatment with a range of concentrations of antiviral prodrugs GCV and BVDU. Controls included mock-infected cells and cells infected with the same amount of HVS/EGFP. Cultures were exposed to the prodrugs for 4 or 7 days before the effects were measured to allow for several rounds of cell division in an asynchronously replicating cell population as GCV acts upon DNA replicating in dividing cells. 1, 3, 4 Figure 5 shows representative experiments where infected K562 cells were exposed to GCV and BVDU for 7 days.
As seen in Figure 5 , neither GCV nor BVDU had any effect on K562 cells infected with a control vector HVS/ EGFP. The percentage of GFP þ cells remained the same (between 80 and 90% depending on an individual experiment) and no decline in cell viability was detected (mean cell viability was 9772% for K562 and 9376% for Jurkat). Mock-infected cells remained viable throughout (mean cell viability was 9773% for K562 and 9871% for Jurkat) and GFP negative. In contrast, HVS/EGFP-TK-infected cells showed a significant reduction in the percentage of live GFP þ cells following treatment with both GCV and BVDU. This effect was dose-dependent and present for prodrug concentrations as low as 1-10 ng/ml. Mean viability at 100 ng/ml prodrug was 78712% BVDU or 85717% GCV for K562 cells, and 81715% BVDU or 8079% GCV for Jurkat cells. This was because residual nontransduced cells remained viable and continued to grow. Figure 6 represents combined data of several independent TK-assay experiments. For adequate comparisons, starting proportions of GFP þ cells (after expansion and with no antiviral agent) were considered 100%, and the effects of GCV and BVDU were recorded as a corresponding reduction in the proportion of green cells. As seen in Fig 6, top panels, at day 4 BVDU treatment of HVS/EGFP-TK-infected cells caused a greater reduction in the percentage GFP þ cells than the equivalent concentration of GCV. This trend remained on day 7 (bottom panels). In general, the effect of both the prodrugs was markedly more prominent on day 7 compared with day 4. Similar results were obtained with Jurkat cells, except that the effect of GCV and BVDU was more dramatic on day 4 then only increasing slightly on day 7 (data not shown).
To further confirm that the loss of EGFP-TK fusion protein expression in these cultures was due to the elimination of EGFP-TK þ cells, responsive to a prodrug, and not due to gene silencing, the TK assay was repeated with higher concentrations of the prodrug (5 mg/ml), and dead cells included in the analysis were visualized using PI staining.
Mock-infected K562 displayed only insignificant spontaneous cell death on day 7 (Fig 7, left panel) , which was not increased by adding a prodrug. The numbers of PI þ K562 cells infected with control vector HVS/EGFP and cultured for 7 days remained constant. The small increase in the number of dead HVS/EGFP-transduced cells, compared with mock-infected cells, was prodrugindependent and possibly resulted from a small toxic effect of the virus (middle panel). In contrast, when K562 were infected with HVS/EGFP-TK virus, the effect of prodrugs on cell viability was substantial (Fig 7, right  panel) . Again, the viral construct itself did not have much effect; it was an addition of prodrugs, which caused increased cell death. A 7-day treatment with high concentration of BVDU killed all EGFP-TK-containing cells (right plot, middle panel); similar treatment with GCV left only a small proportion of GFP þ cells alive (right plot, bottom panel). Altogether, these results proved that the TK present in the infected cells as an EGFP-TK fusion protein was functionally active, and able to activate prodrugs, which subsequently killed infected cells.
Human colorectal and pancreatic cells are susceptible to infection by HVS
HVS/EGFP-TK vector may also be used for local therapy designed to kill tumor cells in situ. HVS has been shown to infect SW480 (colon adenocarcinoma cell line) and Mia PaCa (pancreatic carcinoma). 27 We went on to screen a broad panel of colorectal and pancreatic cell lines, using the HVS/EGFP construct. Confluent cells were infected at high MOI (B10) and low MOI (B0.01). Infected cells were left for 24-48 hours and the presence of green cells was examined visually using a fluorescent microscope (Fig 8a and b) .
All eight cell lines studied were infectable by HVS/ EGFP but to different degrees. Three cell lines (HCT116, SW948 and Mia PaCa) showed particularly high levels of GFP þ cells, even when infected at low MOI. These were chosen for further study in which each cell line was infected at a range of MOI, and was analyzed 24 hours later for the presence of GFP þ cells by flow cytometry (Fig 8c) . Dead cells were excluded from the analysis. All three chosen cell lines were remarkably susceptible, 100-fold higher than that of K562 cells and similar to that of OMK cells. It is worth noting, however, that in contrast to OMK cells the infection was nonpermissive (no infectious virus particles were found in the supernatant) and did not cause direct cell lysis (data not shown). Similar to other adherent human cell lines infected with HVS, some spontaneous cell detachment always occurred as a result of overcrowding. An MOI of 10 resulted in 490% GFP þ cells in all cell lines and was therefore used in subsequent experiments to determine TK expression and activity upon infection with HVS/ EGFP-TK vector. As a suicide vector for in situ therapy, the HVS/EGFP-TK episome needs to be maintained only long enough for sufficient TK expression to cause cell death when treated with prodrugs. Therefore, the parameter of transduction stability was not characterized in these cell lines.
Ablation of HVS/EGFP-TK-infected colorectal and pancreatic adherent cell lines
The TK-assay was next employed to test HCT116, SW948 and Mia PaCa cell lines. A single concentration of 100 ng/ ml of either BVDU (0.3 mM) or GCV (0.4 mM) was chosen as it previously produced a consistent and significant response in both K562 and Jurkat cells. By day 4 BVDU treatment had significantly reduced the number of green, infected cells in each of the three cells lines tested. Mean standardized results from several experiments, each conducted as multiple samples, were as follows: HCT116 (1273%) (n ¼ 6), SW948 (872%) (n ¼ 4) and Mia PaCa (1273%) (n ¼ 10). This corresponded to over 88% reduction in the number of green cells compared to ''no drug'', HVS/EGFP-TK-infected control. The effect was similar in magnitude to the decline observed in Jurkat cells (472%) at the same time point and concentration of BVDU. In K562 cells, similar effects were obtained only after longer BVDU treatment (7 days, 1773%). These results showed that HVS/EGFP-TK was able to deliver functionally active TK into colorectal and pancreatic cell lines.
While in K562 cells BVDU had a more profound effect than GCV, in colorectal cell lines the opposite was true. The effect of 100 ng/ml GCV on HVS/EGFP-TK-infected HCT116 and SW948 cells was seen as a significant increase in the number of both dead (PI þ ) and dying cells. In fact, the effect of 100 ng/ml GCV (0.4 mM) on HCT116 was similar to treatment of K562 cells with as much as 5 mg/ml GCV (20 mM). However, the action of GCV on the HVS/EGFP-TK-infected HCT116 and SW948 cells also significantly altered the size and granularity of the surviving cells, to the extent that it was not possible to obtain flow cytometry data that accurately quantified the killing effect observed. The response of the pancreatic cell line Mia PaCa to GCV was less dramatic, cells retained a similar morphology and effects were quantifiable by flow cytometry: an initial gradual decline in the proportion of live GFP þ cells was followed by the accumulation of dying and dead cells by day 7 of treatment. Mia PaCa cells infected with HVS/ EGFP-TK and treated with GCV for 7 days that remained live in culture had a standardized mean of 13713% green cells (n ¼ 6), corresponding to over 87% reduction in the number of green cells compared to the ''no drug'', HVS/EGFP-TK-infected control.
These results demonstrated that compared with the human leukaemic K562 cells, colorectal and pancreatic cells lines were more susceptible to HVS/EGFP-TK infection and were more sensitive to treatment with GCV or BVDU. In fact, this increased responsiveness to prodrugs could be a likely result of the increased uptake of the viral vector, so that more TK-expressing viral episomes were present in individual cells at the time of treatment. 
Discussion
This is the first report of TK incorporation into a nonpathogenic HVS vector. The viral vector was constructed via a cosmid-based approach and the correct insertion was checked by DNA sequencing and expression immunoblotting. The new virus was grown to high titres similar to wild type and could infect K562 cells to the same levels.
Previous HVS constructs involved a reporter gene such as EGFP, but in conjunction with a selective gene such as neo R , 25, 27, 31 with which HVS episome could be maintained under selective pressure. 27 Another HVS-based construct was based on the strain containing the transforming genes Stp and Tip (that may be nontransforming in some non-human primate cells, but still could induce growth transformation of human T-lymphocytes). 32, 33 We believe that our work fills the gap in the existing research in that we are using a nontransforming strain of HVS and also a TK suicide gene cassette that has a strong therapeutic value. Moreover, in this study TK was fused with EGFP to flag the infected cells, also a novel approach, which enabled us to confirm that the elimination of cultured cancer cells was a direct result of TK action, and not spontaneous death due to prolonged culture.
We were able to transfect cells to a high level (490%) by adapting the MOI to the respective cell line being used. Expression of HVS episomal EGFP gene was detectable through more than 40 cell divisions in both K562 and Jurkat cell lines. Retention of episome expression was calculated as 492% for both viral constructs and cell lines. Stevenson et al observed a retention of EGFP phenotype in HVS/EGFP/neo R -transduced Jurkat cells as 495% per division, 31 and in conjunction with gardella gel analysis showed that this was due to loss of HVS episome, rather than due to virus toxicity or epigenetic effects. With HVS/EGFP-TK we observed a similarly high degree of persistence after transduction, without the requirement for selection. This allows for ex vivo transduction and expansion before reinfusion of therapeutic cells to recipients, as selection cannot be used for in vivo applications. Owing to the incorporation of EGFP in the construct, there is also the possibility of enrichment of transfected cells by fluorescence-activated cell sorting (FACS) before reinfusion. Finally, we tested our construct in rapidly dividing cancer cell lines (K562 doubling time B24 hours); however, primary tumour cells grow much slower and would therefore retain the episome for a correspondingly longer time.
The functional expression of TK was then shown by the response of HVS/EGFP-TK-transduced K562 cells to certain prodrugs. We were aware that HVS encodes its own TK gene that may also be sensitive to GCV or BVDU therefore its activity in human cells was monitored by the control HVS/EGFP vector, which demonstrated no discernible TK activity. The HSV TK gene in conjunction with the prodrug GCV is currently the most widely used suicide gene system. 1 Direct comparisons of killing effects using our construct and other published data is difficult primarily due to lack of a uniform method of determining GCV activity, for both in vitro and in vivo applications. Alternative methods include assessing tumour volume, 17 replication inhibition of HVS-TK virus replication 25 and TK enzyme assays measuring the phosphorylation of tritiated GCV. 37 The majority of published data refers to retrovirus-transduced cells (100% transduction of a TK clone), examined by cell viability in response to GCV. 16, 12 These data closely equate to our experiments, which quantified the PI-GFP þ proportion of cells, that is, viable transduced cells. We employed a wide range of different GCV doses for varying time periods, the significant response of our HVS/EGFP-TK construct to 100 ng/ml GCV (0.4 mM) or less, is certainly as good as and possibly better than published data using retroviral constructs. Ma¨kinen et al 16 achieved a reduction to B33% of viable TK retrovirus transduced DSL-6A/C1 (rat pancreatic carcinoma) cell after 4 days treatment with 100 ng/ml of GCV. Whereas Fareed et al 12 observed a reduction to B11% of viable TK retrovirus-transduced murine embryonic stem cells after 7 days of treatment with 200 ng/ml of GCV. In our experiments, a significant difference between the rate of response of the Jurkat versus the K562 leukaemic cell lines was observed using the same viral construct, indicating that the killing effect is very dependent on the target cell line. After 4 days of treatment with 100 ng/ml of GCV, Jurkats were reduced to B21% viable green cells and K562 to B75%, then by day 7 the figures were further reduced to B4% for Jurkat and B28% for K562. However, as expected both the HVS/EGFP-TK-transduced cell lines were ablated by the administration of GCV in a dosedependent manner.
One of the disadvantages of GCV in in vivo TK gene therapy systems is GCV toxicity, particularly to haematopoetic cells restricting the maximum dose used in humans to 10 mg/kg/day. 38,39,1 (however, there is a new Figure 8 The effect of high concentration of prodrugs (5 mg/ml) on viability of HVS/EGFP-TK-and HVS/EGFP-infected K562 cells in 7-day culture. Mock-infected cells were also included as a negative control. Dot plots show the distribution of PI-(alive), PI þ (dead), GFP-(non-green) and GFP þ (green) cells. Dead cell population is marked by an arrow.
oral analogue of GCV, Valganciclovir). Therefore, the HVS/EGFP-TK vector was also tested against the thymidine analogue BVDU, which is a more efficient and less toxic prodrug than the guanine analogue GCV. Our results with the HVS/EGFP-TK construct in K562 and Jurkat cells confirmed that BVDU was more effective than GCV and in the case of Jurkat cells dramatically reduced the proportion of GFP þ cells to 472% in just 4 days of 100 ng/ml BVDU (0.3 mM). It is known that human blood platelets contain thymidine phosphorylase (TPase), which may induce rapid intracellular degradation of certain nucleosides and their analogues, including BVDU. 5 However, BVDU has been used as a systemic oral treatment against disseminated Varicella zoster virus (VZV) infections with no toxic side effects, 40, 41 as BVDU is active against VZV TK as well as HSV TK.
The small proportion of viable green HVS/EGFP-TKtransduced cells that appear to survive prodrug treatment can be explained in several ways: the prodrug dose may be insufficient for total eradication -Ma¨kinen et al, 16 for example, used concentrations as high as 100 mg/ml GCV, but we chose to remain within a concentration range that did not exhibit toxic effect upon untransduced cells. We favour the alternative opinion that GCV and BVDU only act upon dividing cells; and that some viable transduced cells may be growth suppressed. Also the phenomenon of alternative splicing of the TK gene, leading to a GCVresistant gene product has been described for HSV1-TK in retrovirus vectors 42, 43 and the same cryptic splice sites occur in the sequence of the HVS/EGFP-TK clone (sequence data not shown).
TK activity varies with the prodrug administered. We have tested our construct against GCV and BVDU, but newer variants that offer increased stability, bioavailability, efficiency and less toxicity exist or are being developed. 44, 5 Alternatively, instead of modifying the substrate, some groups 35 have chosen to mutate the HSV TK enzyme itself to broaden its substrate specificity and/ or enhance its activity. Mutations in the putative nucleoside binding site (codons 159-174, Kokoris and Black 35 ) can increase activity up to two orders of magnitude of GCV concentration, depending on the cell line.
14 The marginal, single amino-acid residue alteration in our HSV type 17 TK gene (alanine to threonine, codon 334) was remote from the nucleoside binding site.
HVS/EGFP-TK was designed to include a suicide gene in a potential gene therapy vector, in order to facilitate ablation of transduced cells when they were no longer required. However, such a vector can also be used to kill tumour cells in situ. When screened against a panel of colorectal and pancreatic carcinoma cell lines, all were susceptible to infection by HVS/EGFP, but to differing degrees. HCT116, SW948 and Mia PaCa were remarkably susceptible to infection, showing a similar MOI response to that of permissive OMK cells. However, no direct cell lysis was observed nor was virus production detected in any of the infected cell lines (data not shown). When the three most susceptible cell lines were transduced with HVS/EGFP-TK and subsequently exposed to 100 ng/ml BVDU, the proportion of GFP þ cells was reduced by over 88% in 4 days, and 100 ng/ml GCV over 7 days had an even greater effect. Other studies have shown that besides direct killing of TK-transduced tumour cells, GCV and BVDU demonstrated the ''bystander effect'', that is, causing the death of neighbouring, noninfected cells. 1 In this case, the membrane impermeable phosphorylated GCV and BVDU (that is, the TK-metabolized prodrugs) can pass through gap junctions into adjacent untransduced cells and cause apoptosis. 45, 46 The bystander effect does not influence suspended leukaemic cell cultures, but it may be a factor in the observed high prodrug sensitivity of TK transduced, adherent colorectal/pancreatic carcinoma cells. This is supported by our observation that GCV has a greater effect than BVDU, which correlates with GCV being known to have a greater bystander effect than BVDU. 47, 9 It has also been proposed that the host immune system may play a major role in in vivo bystander killing.
1 This could also explain ''distant bystander'' effects observed in mice, in which not only were TK þ tumours eradicated, but remote untransduced tumours were also affected. 48 Furthermore, when experimental animals, which had eradicated TK þ tumours, were challenged with untransduced tumour cells the new malignancies were rejected or delayed in growth -the so-called ''vaccination'' effect. 49 In conclusion, we have generated a noncytopathogenic viral gene therapy vector, HVS/EGFP-TK, that can infect a wide range of cell types. This vector can easily be produced at high titres, but viral replication has not been detected in transduced human cell lines. The incorporation of the reporter gene EGFP allows easy monitoring of infection and the TK gene facilitates a suicide mechanism following the administration of the prodrugs GCV or BVDU. The HVS/EGFP-TK vector can now be further developed by inclusion of an expression cassette for a therapeutic gene of interest. Alternatively, it could be directly utilized as an antitumour agent in its current form and therefore requires in vivo testing in model systems. These results suggest that HVS/EGFP-TK has great potential for gene therapy applications.
Methods
Cells
HVS permissive Owl Monkey Kidney cells (OMK-637, ECACC, Salisbury, UK) were grown in Dulbecco's modified MEM (DMEM) media containing 10% (v/v) foetal calf serum (FCS) (both from Gibco, Paisley, UK) and used at passages 21 to 30 in all experiments. Human leukaemic cell lines Jurkat (T cell lymphoblastic leukaemia) and K562 (chronic myelogenous leukaemia) (both a gift from Dr RA Jones, Leeds General Infirmary, Leeds) were grown in RPMI 1640 (Gibco)/5% (v/v) FCS. Human pancreatic carcinoma cell lines PANC-1, Mia PaCa and BxPC3 and human colorectal cell lines HCT116 (colon carcinoma), HRT18 (rectum-anus adenocarcinoma), HT29 (colon carcinoma grade II), SW480 and SW948 (both colon adenocarcinomas) (all a gift from the Department of Surgery, St James University Hospital, Leeds) were grown in DMEM/10% FCS. All the media were supplemented with antibiotics (100 U/ml penicillin, 100 mg/ml streptomycin, both from Gibco).
Construction of EGFP-TK cosmid and HVS/EGFP-TK recombinant virus
HVS-TK recombinant virus was created using a cosmidbased approach. 29 A set of five cosmids containing the full HVS genome was a kind gift of Dr A Ensser, University of Erlangen, Germany. Cosmid 331EGFPÄ Bst1107I had been previously manipulated, whereby the genes StpC and Tip (necessary for transformation and pathogenesis) 33, 32 were deleted and an EGFP expression cassette was included. 29 The only single restriction site available in the cosmid was the BamHI site, within the multiple cloning site at the 3 0 -end of the EGFP gene. 29 All restriction enzymes for further manipulation of the cosmid 331EGFPDBst1107I were supplied by New England BioLabs (Hitchin, UK). The TK gene sequence was amplified from HSV (type 17) genomic DNA by PCR with oligonucleotide primers 5 0 TK BglII: dCCT TGT AGA AAG ATC TAT GGC TTC GTA CC and 3 0 TK BamHI: dTTG TCT GGA TCC GTG TTT CAG TTA GCC. The resulting DNA fragment (B1.1 kb) was digested with BamHI and BglII to generate the appropriate overhanging ends for ligation into BamHI linearized and calf intestinal phosphatase (CIP)-treated cosmid 331EGFPÄ BstI1071. Ligation products were transformed into ElectroMAX DH10B cells (Invitrogen, Paisley, UK) by electroporation (45 ml cells in a 0.1 cm cuvette, 2.5 mF and 100 O). Transformants were screened by colony PCR using TK primers. DNA from positive clones were analyzed by restriction analysis with enzyme combinations of NotI/BamHI, KpnI/NotI and KpnI/BamHI, to determine the orientation of the insert. Thus, the HVS-TK sequence was fused onto the 3 0 -end of EGFP while maintaining coding sequences in frame. The DNA sequence spanning the EGFP-TK fusion point and along the length of the insert was confirmed by ABI sequencing. A working amount of the clone cosmid 331 EGFP-TK Ä BstI1071 was isolated using Qiagen large construct kit (Crawley, UK).
To generate the recombinant HVS/EGFP-TK virus vector of 0.6 mg each of the 5 NotI linearised cosmids were mixed with 300 ml DMEM containing 15 ml lipofectamine (Invitrogen, Paisley, UK). After B40 minutes, required for liposome formation, 2.4 ml of serum-free medium was added and the lipofectamine mixture was added to rinsed, semiconfluent OMK cells grown in a 25 cm 2 flask (Corning Costar, High Wycombe, UK). After 5 hours incubation, the cells were washed twice with phosphatebuffered saline (PBS, Gibco) and then incubated in DMEM/10% (v/v) FCS. After 24-48 hours, the medium was removed and replaced with fresh DMEM/10% (v/v) FCS for a further 2-3 weeks. During this time, the formation of green viral plaques was monitored using a Zeiss fluorescent microscope (Zeiss, UK). OMK cells grown in three 25 cm 2 flasks were transfected, progressed to cytopathic effect (CPE) and were harvested to produce the first stock of HVS/EGFP-TK.
Growth and titration of virus vectors HVS/EGFP-TK and HVS/EGFP
Control vector C488 EGFPÄ Bst1107I (HVS/EGFP) was constructed as described previously. 29 . HVS/EGFP and HVS/EGFP-TK vectors were grown in OMK cells in 1700 cm 2 roller bottles (Corning Costar,) in DMEM, containing 5% FCS until complete CPE was observed. Cell debris was removed by low speed centrifugation 2600 g for 20 minutes. The virus pellet was obtained from the culture supernatant by centrifugation at 16,000 g for 90 minutes, then resuspended in 1 ml of the culture medium per roller bottle and stored at À801C. Virus titration experiments were performed on confluent OMK cells in replica wells of 24-well plates (Corning Costar) using 200 ml of 10-fold virus dilutions. After 2 hours of incubation at 371C, the virus was removed and 0.5 ml of 1.2% methylcellulose (Stem Cell Technologies, UK) was placed in each well. Green plaques were scored 4-7 days later. The typical yield for HVS/EGFP was 2.7 Â 10 
Western blotting
Confluent OMK cells grown in a 25 cm 2 flask were infected with HVS/EGFP-TK at an MOI of 10 and cultured for 48-72 hours until at least 50% CPE was observed. Control treatments included infections with the same amount of HVS/EGFP vector or media only (mockinfected control). Transfected cells were harvested, processed and run on a standard 10% SDS-polyacrylamide gel. Proteins were subsequently transferred onto nitrocellulose membranes (VWR International Ltd, Poole, UK) and the membranes treated with anti-GFP polyclonal rabbit antiserum (1:500, Clontech living colours A.v. peptide antibody). Nonspecific binding was blocked with PBS/5% milk powder/0.1% Tween throughout all incubation stages. Binding of the primary antibody was detected with goat anti-rabbit Ig-horseradish-peroxidase (1:1000, DAKO, Denmark). Protein bands were visualised by enhanced chemiluminescence detection according to the manufacturer's instructions (Perbio, USA).
Analysis of susceptibility of human cells to infection with HVS/EGFP and HVS/TK vectors by flow cytometry
Adherent cell lines (HCT116, HRT18, HT29, SW480, SW948, BxPC3, Mia PaCa and Panc1) were grown in 12-well plates (Corning Costar) and confluent cells (B5 Â 10 5 /well) were infected with 10-fold dilutions of virus vectors in a final volume of 300 ml medium for 2 hours. In the case of cell lines grown in suspension (Jurkat and K562) aliquots of 5 Â 10 5 cells were pelleted and mixed with 10-fold dilutions of virus vector in a final volume of B330 ml medium. After 2 hours incubation at 371C with continuous shaking, the cells were washed with PBS and grown in the appropriate medium for a further 48 hours. For the analysis of EGFP production by flow cytometry adherent cells were harvested by trypsin/EDTA treatment. In all experiments, propidium iodide (PI, Sigma, Poole, England) at 1 mg/ml was added prior to acquisition to exclude dead cells from the analysis. EGFP fluorescence (GFP þ ) was measured on the FL1 (green) channel. PI-positive dead cells were detected on the FL3 (red) channel. Data were acquired using an Epics XL/ MCL flow cytometer and analyzed using the WinMDIv2.8 program.
Analysis of functional expression of TK, rendering cells infected with HVS/EGFP-TK sensitive to GCV and BVDU (TK assay) GCV and BVDU (Sigma) were used at concentrations ranging from 1 to 1000 ng/ml in a 10-fold dilution series. Jurkat and K562 cells were initially infected with HVS/ EGFP-TK at an MOI of 100 to achieve nearly 100% EGFP þ cells by 48 hours postinfection (see Results). The more susceptible HCT116, SW948 and Mia PaCa cells were infected at an MOI of 10. The infected cells were expanded and TK functional assays were conducted in 24-well plates with 2 Â 10 5 cells/well for Jurkat and K562; or six-well plates with 6.3 Â 10 5 cells/well for HCT116/ SW948 and 1 Â 10 6 cells/well for MIAPaCa. In order to avoid cell death through overcrowding, rather than TKmediated killing, on day 4 of the culture adherent cells were fed with fresh media supplemented with the same concentration of GCV or BVDU. K562 and Jurkat cells were fed 1 ml fresh medium supplemented with prodrug on days 2 and 4. On day 4, suspended cell cultures were also divided, half the sample was used for flow cytometry analysis, the other half cultured until analysis on day 7.
Samples were analyzed by flow cytometry to quantify the proportion of live, infected cells by measuring the proportion of GFP þ PIÀ cells. HVS/EGFP vector and mock-infected cells were used to monitor non-TKmediated cytotoxic effect of GCV or BVDU at the concentrations used.
